Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
The Methodist Hospital Research Institute
Singapore General Hospital
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center